Bausch Health Companies Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BHC in the last 30 days.
See all $BHC insider activity →Bausch + Lomb is set to report Q3 earnings, with analysts expecting $0.21 EPS on $1.37B revenue, up 19% and 7% YoY respectively. The company faces FDA scrutiny over a facility inspection and recent leadership changes. Its dry eye treatment, Miebo, is a key focus for investors.
Bausch Health Canada, a subsidiary of Bausch Health Companies (BHC), announced expanded public reimbursement for PrOKEDI, a long-acting schizophrenia treatment, in seven Canadian provinces and federal drug plans. The Phase 3 PRISMA-3 study showed significant improvements in PANSS and CGI-S scores. BHC stock is up 1.16% at $6.38.
Bausch Health (BHC) and Salix Pharmaceuticals reported a pilot study showing improved adherence to cirrhosis care guidelines. The study, involving 4,251 patients, found increases in office visit adherence, laboratory monitoring, and other care metrics. Shares are up 4.55% at $6.32.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BHC (Bausch Health Companies Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BHC coverage spans financial news, earnings and technology.
Anticipated earnings beat could drive modest upside, but FDA warning and CEO transition may cap gains.
The reimbursement expansion should improve sales outlook for PrOKEDI, creating modest upside pressure on BHC stock.
Positive clinical pathway data may boost investor confidence in Bausch Health's gastroenterology franchise.
Leadership transition may cause short‑term uncertainty.
Analyst rating and price target upgrade suggest upside potential.
AlphAI scores every news story that mentions BHC with an AI model for sentiment and relevance, and aggregates insider trades from Bausch Health Companies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bausch + Lomb is set to report Q3 earnings, with analysts expecting $0.21 EPS on $1.37B revenue, up 19% and 7% YoY respectively. The company faces FDA scrutiny over a facility inspection and recent leadership changes. Its dry eye treatment, Miebo, is a key focus for investors.
3 min readBausch Health Canada, a subsidiary of Bausch Health Companies (BHC), announced expanded public reimbursement for PrOKEDI, a long-acting schizophrenia treatment, in seven Canadian provinces and federal drug plans. The Phase 3 PRISMA-3 study showed significant improvements in PANSS and CGI-S scores. BHC stock is up 1.16% at $6.38.
1 min readBausch Health (BHC) and Salix Pharmaceuticals reported a pilot study showing improved adherence to cirrhosis care guidelines. The study, involving 4,251 patients, found increases in office visit adherence, laboratory monitoring, and other care metrics. Shares are up 4.55% at $6.32.
2 min readJoseph Appio, CEO of Bausch Health, is now interim CEO of Bausch + Lomb. The companies expect to raise full-year 2026 adjusted EBITDA guidance based on strong Q3 performance. Brent Saunders, former Bausch + Lomb CEO, has departed. Appio's leadership has seen 13 consecutive quarters of revenue and EBITDA growth at Bausch Health.
2 min readRBC Capital reiterated a Sector Perform rating on Bausch Health (BHC) with a $9.00 price target, citing undervaluation. The firm projects Q3 2026 revenue of $2.79B and adjusted EBITDA of $1.037B. BHC stock has gained 7.3% in the past week. The company will report Q3 results on October 28, with key focus areas including patent litigation and margin durability.
2 min readBausch + Lomb plans to begin clinical trials in 2027 for BL1243, an oral treatment for dry age-related macular degeneration (AMD). The FDA supported the initial study design, and Phase 2 advancement is expected if no unexpected findings occur. BL1243 aims to address a significant unmet need in early-stage dry AMD, with potential for a convenient, non-invasive treatment option.
1 min readBausch + Lomb's Xiidra and Miebo combination therapy significantly improved dry eye symptoms in patients who had previously tried over four treatments. A study of 68 patients showed reduced dryness, improved staining, and better tear metrics. Most patients continued using both drops for about 194 days. Bausch + Lomb plans a phase 3 study for a combined drop.
2 min readBausch Health (BHC) and YUN are expanding their probiotic skincare partnership into six new markets, including Mexico and Central/Eastern Europe. This follows BHC's raised full-year guidance after Q2 2026 revenue of $2.85B (+13% YoY) and EPS of $1.26 (+40% YoY). The International segment grew 10% (5% organic), while the Diversified segment, including Dermatology, remained flat.
2 min readBausch + Lomb received CE Mark approval for its SeeLyra femtosecond laser in Europe, allowing a limited rollout soon and broader availability in 2027. The laser is designed for cataract, LASIK, and corneal procedures, offering precision and flexibility. The company is also seeking approvals in other markets, including the U.S.
2 min readThe TSX rose 1.5% on Thursday, led by miners and tech, after Fed Governor Waller suggested patience on rate hikes. Celestica gained 11.4%, Wesdome Gold 8%, and Thomson Reuters 5%. The Canadian dollar strengthened to 72.53 cents. U.S. markets also climbed, with the Dow up 1.2%.
2 min read
